VEGFA and hepatocellular carcinoma: Regarding experimental biomarkers, a subanalysis of the SHARP cohort showed a prognostic value of vascular endothelial growth factor (VEGF) and angiotensin 2 (Ang2) in patients with advanced HCC concerning median OS regardless of treatment with sorafenib or placebo, while a significant role in predicting the response to sorafenib treatment could not be shown [21].